Treatment based On BRCA1 level does not increase survival of stage II/III NSCLC N+ resected patients

(International Association for the Study of Lung Cancer) Research shows that treating stage II and III non-small cell lung cancer (NSCLC) N+ resected patients with customized chemotherapy treatment based on their specific BRCA1 expression levels, as opposed to providing the standard treatment, did not increase overall survival rates among those patients who received individualized CT treatment. Dr. Bartomeu Massuti of Alicante University Hospital in Spain presented his findings today at the International Association for the Study of Lung Cancer (IASLC) 18th World Conference on Lung Cancer (WCLC) in Yokohama, Japan.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news